-
Johnson and Johnson's Posson Tatterser gets NMPA approval to treat pulmonary hypertension in children
Time of Update: 2020-06-08
recently, Johnson and Johnson's Janssen Pharmaceutical (http:// company (http:// Actelion announced that Posson tatters (full-®, English brand name: Tracleer, generic name: bosentan) (spec: 32m
-
FDA grants SpringWorks nirogacestat breakthrough treatment
Time of Update: 2020-06-08
hard fibroids are a rare soft tissue tumor that is deactivation and can lead to disfigurement It can quickly invade the surrounding healthy (http:// tissue, causing severe pain, internal bleeding
-
FDA approves gene Tektrone (Merycin) in combination with glucocorticoids for use in children's GPA and MPA
Time of Update: 2020-06-08
recently, Swiss Pharmaceutical (http:// giant Roche's GeneTek announced that the U.S Food and Drug (http:// Authority ( FDA (http:// ) has approved Rituxan (Mera, rituximab, ritusxima) in co
-
Paclitaxel and encequidar combined to treat breast cancer in key phase 3 clinical study reached the main endpoint
Time of Update: 2020-06-08
Today, Athenex (http:// announce its oral formula, which combines paclitaxel and encequidar, to reach the main point in a key Phase 3 clinical study to treat metastatic breast cancer About Enceq
-
FDA grants Astex pharmaceutical anti-cancer drug ASTX727 orphan drug
Time of Update: 2020-06-08
recently, Japanese pharmaceutical company Otsuka Pharmaceuticals (http:// wholly-owned sub- company (http:// Astex Pharmaceuticals announced that the U.S Food and Drug (http:// Administrati
-
Green leaf pharmaceutical ansofasin reprieve tablet (LY03005) has been submitted for clinical trials in Japan
Time of Update: 2020-06-08
Recently, the http:// Group of Green leaf Pharmaceutical s announced that its new compound for the treatment of depression, the Antufaxin Reprieve (LY03005), has submitted a clinical trial (http
-
NMPA accepts new drug application for Tanbey Mitsubishi Tenelia 20mg tablet
Time of Update: 2020-06-08
recently, Japanese pharmaceutical company Mitsubishi Pharmaceutical (http:// (http:// announced that China's State Drug (http:// Regulatory Authority (NMPA) has accepted a regulatory applica
-
Alkahest achieves positive results in clinical trials of the treatment of Alzheimer's disease in Phase 2 of the research therapy GRF6019
Time of Update: 2020-06-08
recently, Alkahest (http:// announced positive results in its treatment of GRF6019, a phase 2 clinical trial (http:// in patients with mild to moderate Alzheimer's disease (AD) GRF6019 consis
-
FDA grants Moderna's mRNA-1893 fast-track eligibility for Zika virus vaccine
Time of Update: 2020-06-08
The U.S Food and Drug (http:// Administration http:// (http:// has granted its a fast-track qualification for the Zika virus vaccine mRNA-1893, the http:// company announced Now, Moderna
-
FDA grants Ridgeback's mAb114 breakthrough drug
Time of Update: 2020-06-08
recently, Ridgeback Biotherapeutics (http:// announced that the u.S Food and Drug (http:// Authority ( FDA (http:// has granted mAb1114 breakthrough drug eligibility (BTD) May 2019, the FD
-
Novartis announces new data on phase III clinical study of anti-inflammatory drug Cosentyx (good) treatment nr-axSpA
Time of Update: 2020-06-08
recently, Swiss Pharmaceutical s (http:// giant Novartis has released new data on the treatment of the anti-inflammatory drug Cosentyx (co-cuminumab, scucciuumab, scochiu) for the efficacy and sa
-
FDA grants bempegal desleukin and Opdivo immunocombination therapy breakthrough drug qualification
Time of Update: 2020-06-08
recently announced jointly with BMS that the U.S Food and Drug (http:// Administration ( FDA (http:// has awarded bempegaldedesleukin (BEMMTR-214) and Opdivo (nivolumab, Navudan) immunocomas b
-
CHMP approves Roche Tecentriq combined caplatin and Abraxane chemotherapy for treatment of NSCLC adult patients
Time of Update: 2020-06-08
Roche recently announced that the European Medicines (http:// Administration (CHMP) Recommended approval of its heavy immunotherapy Tecentriq combined caplatinum and Abraxane (albumin-combined ye
-
GlaxoSmithKline submits new drug application for daprodustat for renal anemia to Japan's Ministry of Health, Labour and Welfare
Time of Update: 2020-06-08
recently, GlaxoSmithKline (GSK) submitted to the Ministry of Health, Labour and Welfare (MHLW) a application for a new drug (http:// (NDA) to approve oral hypoxic-inducing factor protalysinase in
-
Sibiman bio-autonomous human-derived supermyoblast injection obtains implicit permission for clinical trials
Time of Update: 2020-06-08
knee osteoarthritis is a common chronic joint disease, also known as degenerative arthritis, characterized by the primary or secondary degenerative change of joint cartilage and bone hyperplasia co
-
FDA approves Epson Bio to expand Dysport injection spree
Time of Update: 2020-06-08
recently, the , epson bio pharmaceutical (http:// company (http:// announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has approved the expansion of the scope of D
-
U.S. Chrysalis lead compound TP508 is qualified by FDA and EJEC orphan drug
Time of Update: 2020-06-08
Recently, according to foreign media reports, the U.S bio pharmaceutical (http:// company (http:// Chrysalis BioTherapeutics announced that its lead compound TP508 was fda (http:// and the E
-
Phase 3 clinical trial of Diroximel fumarate for treatment of RRMS yields positive top-line results
Time of Update: 2020-06-08
recently, the (http:// of the company of Alkermes and Biogen announced positive top-line results a Phase 3 clinical trial (http:// for the treatment of recurrent recurrent multiple sclerosis (R
-
Lilly new drug Galgality (galcanezumab-gnlm) achieves positive results in Phase 3 clinical trial IN CONQUER
Time of Update: 2020-06-08
today, ( http:// announced positive results in the of the new drug, http:// in the CONQUER of the Phase 3 Clinical Trial (http:// About Emgality Emgality is a humanized CGRP monoclonal a
-
Yan Noi's new antibiotic cefiderocol treatment hospital obtained pneumonia adult patients 3 study reached the main endpoint
Time of Update: 2020-06-08
recently, Japan's Shionogi company (http:// announced that it had developed a new antibiotic, cefiderocol, to reach the main endpoint of the experimental (http:// in the phase 3 study of APEKS
